Biolab, a Brazilian pharmaceutical company, has been selected by the UN-backed Medicines Patent Pool to manufacture and sell baloxavir marboxil (Xofluza), Roche’s single-dose oral influenza treatment, in Brazil under a voluntary licensing agreement covering 129 low- and middle-income countries.
Media partner
MARKET ACCESS · ANTIVIRAL LICENSING · SEPTEMBER 26, 2026 · BRAZIL
Announced at a United Nations General Assembly side event on pandemic preparedness, a voluntary licensing agreement has positioned Biolab, a Brazilian pharmaceutical company, to manufacture and sell baloxavir marboxil — Roche’s single-dose oral influenza antiviral marketed as Xofluza — in Brazil. The sublicense was granted by the Medicines Patent Pool (MPP), a UN-backed public-health body, under a broader agreement with Roche covering 129 low- and middle-income countries, according to the MPP. Biolab is one of 11 manufacturers sublicensed by the MPP.
The announcement, published by the MPP on September 25, 2026, places Biolab inside a licensing architecture that gained institutional credibility during the COVID-19 pandemic, when the MPP model was used to accelerate access to antivirals at scale.
What the Sublicence Covers
The drug is a single-dose oral antiviral that World Health Organization (WHO) guidelines conditionally recommend for non-severe influenza in patients at high risk of severe illness, and for post-exposure prophylaxis in people at very high risk of hospitalisation. Under the licence, supply of generic versions is subject to regulatory authorisation, according to the MPP; no Agência Nacional de Vigilância Sanitária (ANVISA), Brazil’s health regulator, filing or approval timeline for a Biolab version has been publicly disclosed.
The MPP’s role is structural: it negotiates voluntary licences with originator companies and sublicences to generic or regional manufacturers in lower-income markets, with the explicit aim of expanding access before patent expiry would otherwise permit it. The model’s relevance to pandemic preparedness is that it pre-positions manufacturing capacity and regulatory dossiers ahead of an outbreak, rather than scrambling to build them during one. Biolab’s selection as the Brazilian sublicensee suggests the MPP assessed the company’s existing production infrastructure as adequate for scale-up — though the specific facility or capacity figures underpinning that assessment have not been disclosed in public materials reviewed for this article.
The ANVISA Clock and the Access Gap
The distance between a sublicense announcement and a dispensable product in a Brazilian pharmacy is defined almost entirely by ANVISA’s registration timeline. ANVISA’s standard review windows vary by product category and priority designation; the company has not stated whether it will seek priority review status, and ANVISA has not issued any public communication on the filing.
This gap matters commercially and for pandemic preparedness alike. Baloxavir marboxil’s value in an outbreak scenario depends on pre-positioned supply, not on a product that enters the registration queue after a pathogen emerges. The MPP model is designed precisely to compress this lag — but the compression is only as fast as the national regulator’s throughput. No analyst estimate of the Brazilian registration timeline has been published in connection with this deal.
On the competitive landscape, Biolab enters a market where influenza antivirals have historically been dominated by oseltamivir (Tamiflu), whose generic versions are widely available in Brazil. Baloxavir marboxil’s single-dose oral regimen and distinct mechanism — it inhibits cap-dependent endonuclease rather than neuraminidase — differentiate it clinically, but the commercial and formulary implications for Brazil’s Sistema Único de Saúde (SUS), the country’s public health system, have not been addressed in public statements by either Biolab or the Ministry of Health. Whether the SUS would procure baloxavir marboxil through a public tender, and at what price, remains unresolved.
Biolab also operates internationally through Exzell Pharma, its Canadian subsidiary, according to Exzell Pharma. The MPP licence allows sublicensees to develop, manufacture and supply generic baloxavir marboxil across the 129-country territory, according to the MPP; Biolab has not publicly specified whether it intends to supply markets beyond Brazil.
The principal friction in this arrangement is not the licensing structure but the regulatory sequencing. A sublicense is a legal instrument; a registered, manufactured, and distributed product is an operational outcome. The two are separated by ANVISA’s review calendar, Biolab’s manufacturing validation process, and any procurement decision by public or private payers. Each of those steps runs on its own timeline, independent of the MPP agreement’s geographic scope or ambition.
What to Watch
- ANVISA filing date for baloxavir marboxil by Biolab, and whether the company applies for priority review designation
- Any Ministry of Health or SUS procurement signal indicating public-sector interest in baloxavir marboxil ahead of or following registration
- Whether Biolab’s sublicense role extends to other countries within the MPP’s 129-country scope, which would materially change the manufacturing volume rationale
The HealthSignals Brief
The signals that move health markets in Latin America and the US — every two weeks, in one PDF.
Free. Unsubscribe anytime.
The deeper signal in this deal is that voluntary licensing, once a mechanism associated primarily with HIV and hepatitis C access campaigns, is now being applied proactively to influenza antivirals in a pandemic-preparedness frame — before a declared emergency, not in response to one. Whether that pre-positioning translates into accessible supply in Brazil depends on a regulatory and procurement sequence that the MPP agreement does not itself accelerate.
Voluntary Licensing Scope
129
Low- and middle-income countries covered by MPP-Roche voluntary license
Single-dose oral
Baloxavir marboxil formulation for influenza treatment and post-exposure prophylaxis
Licence terms: Sublicensees can develop, manufacture and supply generic baloxavir marboxil in 129 countries, subject to regulatory authorisation.
Source: Medicines Patent Pool (25 September 2026)
Why this is relevant
Patients
Baloxavir marboxil, a single-dose oral antiviral that WHO guidelines conditionally recommend for high-risk patients with non-severe influenza and for post-exposure prophylaxis in very-high-risk contacts, may become available in Brazil in a Biolab-made version once registered by ANVISA — a timeline that has not been publicly disclosed and that defines when, if ever, patients gain access to that version.
Industry
Biolab’s selection as an MPP sublicensee positions it in pandemic-preparedness antivirals, a category that could attract public procurement interest from the SUS but requires successful ANVISA registration before any commercial or public-sector revenue is realised.
Payers
The SUS, Brazil’s public health system, has not issued any public statement on procurement interest in baloxavir marboxil, and no pricing or formulary pathway has been disclosed; the commercial and public-sector reimbursement implications of the sublicense remain entirely unresolved at this stage.
Litigation
No litigation risk has been identified in connection with this voluntary licensing transaction; the MPP model is structured to operate within existing patent frameworks through negotiated agreements, and no legal challenge to the Roche-MPP arrangement has been reported in public sources reviewed for this article.
Sources: Medicines Patent Pool; Medicines Patent Pool (baloxavir licence); Infectious Diseases & Immunity (WHO 2024 influenza guideline review); Exzell Pharma
THE HEALTHSIGNALS BRIEF
A fortnightly PDF compiling our analysis on pharma, medical devices, health policy and epidemiology across Latin America and the United States.
Built for pharma, market-access, regulatory, policy and investor teams, with the main findings of our gated reports included.
Your subscription could not be validated.
You have successfully subscribed.
